[177Lu]JH020002

镥[177Lu]JH020002

Report date: 2025/11/20 13:28:14
NME

Base Information

Drug Name[177Lu]JH020002
Drug Alias NameLu 177 JH020002 injectionLu 177 JH020002注射液[177Lu]JH020002177-Lu JH-020002Lu 177 JH020002 +[9] 
ClassificationRadiation-emitting products > Radioactive therapeutic agentRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionProstate-Specific Membrane Antigen modulatorsIonising radiation emitters
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBivision Biomedical Technology (Nanjing) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBivision Pharmaceuticals IncBivision Biomedical Technology (Shanghai) Co LtdBivision Biomedical Technology (Nanjing) Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms, Castration-ResistantProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A